New phase 3 analyses show that a single dose of regen-cov® (casirivimab and imdevimab) provides long-term protection against covid-19

Tarrytown, n.y., nov. 8, 2021 /prnewswire/ -- single dose of regen-cov (1,200 mg subcutaneous) reduced the risk of covid-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1 during the 8-month assessment period there were 0 hospitalizations for covid-19 in the regen-cov group and 6 in the placebo group the fully human antibodies in regen-cov were developed to provide long-lasting protective effects without any artificial mutations or sequences regeneron pharmaceuticals, inc. (nasdaq: regn) today announced additional positive results from a phase 3 trial jointly run with the national institute of allergy and infectious diseases (niaid), which assessed use of a single dose of investigational regen-cov® (1,200 mg administered via 4 subcutaneous injections) to prevent covid-19 in uninfected individuals.
REGN Ratings Summary
REGN Quant Ranking